Abstracts & Publications
Recent Publications
Date |
Location |
Title |
Details |
14 Mar 2023 |
13th World ADC Conference, London |
Novel Target Identification Using Oxford BioTherapeutics' Proprietary Proteomics Target Discovery, OGAP(R), for First-in-Class ADCs and Other Antibody Therapeutics |
View here |
14 Mar 2023 |
13th World ADC Conference, London |
Oxford BioTherapeutics and ImmunoGen Partner to Develop Multiple First-in Class Antibody-Drug Conjugates in Cancer Indications with High Unmet Clinical Need |
View here |
22 Oct 2022 |
Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2022 Sep 27:CCR-22. |
A Novel B7-H6-targeted IgG-like T-cell Engaging Antibody for the Treatment of Gastrointestinal Tumors. |
View here |
8 - 13 April 2022 |
AACR Annual Meeting 2022, New Orleans, Louisiana |
Potential novel immuno-oncology mechanism revealed during translational Phase I immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient. |
View here |
8 - 13 April 2022 |
AACR Annual Meeting 2022, New Orleans, Louisiana |
Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results |
View here |
3 – 7 June 2022 |
ASCO Annual Meeting 2022, Chicago |
Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results |
View here |
Selected Past Publications
Date |
Location |
Title |
Details |
27-28 April 2020 |
AACR Annual Meeting 2020, Virtual meeting. |
Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile |
View here |
09 January 2020 |
Haematologica 2020; Volume 105(11):2584-2591 |
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models |
View here |
21 June 2019 |
Mol Cancer Ther 2019;18:1533–43; AACR |
MEN1309/OBT076, a First-In-Class Antibody– Drug Conjugate Targeting CD205 in Solid Tumors |
View here |
14-18 April 2018 |
AACR Annual Meeting 2018, Chicago, Illinois |
Preclinical Development of a Novel Antibody-Drug Conjugate Targeting “Cold” Tumors |
View here |
14-18 April 2018 |
AACR Annual Meeting 2018, Chicago, Illinois |
Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development |
View here |
1-5 April 2017 |
AACR Annual Meeting 2017, Washington, D.C., USA |
Analysis of tumor infiltrating lymphocytes and in vitro exhausted T cell models to identify unique Immuno-Oncology targets |
View here |
16-20 April 2016 |
AACR Annual Meeting 2016, New Orleans, Louisiana |
The use of proteomics to analyse whole tumors and identify unique stroma cell targets for antibody-based therapeutics |
View here |
18-22 April 2015 |
AACR Annual Meeting 2015, Philadelphia, Pennsylvania |
The use of proteomics to analyze whole tumors and identify unique immuno-oncology targets for antibody-based therapeutics |
View here |
5-9 April 2014 |
AACR Annual Meeting 2014, San Diego, CA |
Proteomics and Selecting the Right Combination of Target and Toxin for Antibody-Drug-Conjugate (ADC) Development |
View here |
31 March - 5 April 2012 |
AACR Annual Meeting 2012, Chicago |
Proteomics highlights which G-protein coupled receptors are candidates for ADC development |
View here |